Reata Pharmaceuticals Inc (NASDAQ:RETA) major shareholder James W. Traweek, Jr. acquired 121,725 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were acquired at an average cost of $24.88 per share, for a total transaction of $3,028,518.00. Following the acquisition, the insider now directly owns 35 shares of the company’s stock, valued at $870.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Reata Pharmaceuticals Inc (NASDAQ RETA) traded up $0.27 during midday trading on Friday, reaching $25.10. The company’s stock had a trading volume of 484,510 shares, compared to its average volume of 202,894. Reata Pharmaceuticals Inc has a 12-month low of $19.48 and a 12-month high of $40.88. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of -0.15.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts expect that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current fiscal year.

Several research firms have weighed in on RETA. Robert W. Baird reissued a “buy” rating and issued a $47.00 target price on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th. Zacks Investment Research raised Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. ValuEngine lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group reiterated a “buy” rating and set a $44.00 target price on shares of Reata Pharmaceuticals in a research report on Friday, October 6th. Finally, Leerink Swann started coverage on Reata Pharmaceuticals in a research report on Wednesday, September 13th. They set an “outperform” rating and a $43.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $54.71.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Emerald Advisers Inc. PA grew its stake in Reata Pharmaceuticals by 40.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock valued at $17,709,000 after purchasing an additional 162,990 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Reata Pharmaceuticals by 60.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock worth $14,712,000 after purchasing an additional 179,124 shares during the last quarter. FMR LLC lifted its holdings in shares of Reata Pharmaceuticals by 74.4% in the 2nd quarter. FMR LLC now owns 414,491 shares of the company’s stock worth $13,114,000 after purchasing an additional 176,885 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Reata Pharmaceuticals by 109.6% in the 2nd quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock worth $9,350,000 after purchasing an additional 154,515 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Reata Pharmaceuticals by 78.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 232,562 shares of the company’s stock worth $7,359,000 after purchasing an additional 101,969 shares during the last quarter. Hedge funds and other institutional investors own 29.61% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Reata Pharmaceuticals Inc (RETA) Major Shareholder James W. Traweek, Jr. Purchases 121,725 Shares” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/reata-pharmaceuticals-inc-reta-major-shareholder-james-w-traweek-jr-purchases-121725-shares/1768167.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.